Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Classement en actions #93
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and... Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Prix de l'action
$137.21
Capitalisation boursière
$170.34B
Changement (1 jour)
-2.76%
Changement (1 an)
28.14%
Pays
US
Échange Gilead Sciences, Inc. (GILD)

Catégorie

Bénéfices pour Gilead Sciences, Inc. (GILD)
Bénéfices en Dec 2025 TTM : $9.80B
Selon les derniers rapports financiers de Gilead Sciences, Inc., les bénéfices actuels de l'entreprise sont de $9.80B. En 2024, l'entreprise a réalisé un bénéfice de $690.00M, une diminution par rapport à celui de 2023 qui était de $6.86B. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Gilead Sciences, Inc. de 2000 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $9.80B 0.01%
2025 $9.80B 1,319.71%
2024 $690.00M -89.94%
2023 $6.86B 17.97%
2022 $5.81B -29.77%
2021 $8.28B 395.99%
2020 $1.67B -67.66%
2019 $5.16B -33.84%
2018 $7.80B -42.35%
2017 $13.53B -20.87%
2016 $17.10B -21.06%
2015 $21.66B 45.79%
2014 $14.86B 253.04%
2013 $4.21B 16.50%
2012 $3.61B -1.07%
2011 $3.65B -6.71%
2010 $3.91B 11.75%
2009 $3.50B 31.03%
2008 $2.67B 17.72%
2007 $2.27B -455.74%
2006 $-638.21M -154.93%
2005 $1.16B 76.99%
2004 $656.42M -491.82%
2003 $-167.53M -328.26%
2002 $73.40M 27.76%
2001 $57.45M -237.08%
2000 $-41.91M 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
$25.73B 162.63%
US
$12.40B 26.59%
GB
$32.58B 232.56%
US
$6.60B -32.66%
US
$16.35B 66.91%
CH